Abstract 244P
Background
To evaluate the practical significance of the effectiveness of the modified coloring solution “CIN-DIAG” in the diagnosis of pathological changes of the cervix.
Methods
The modified CIN-DIAG coloring solution is a sterile cotton swab on a plastic stick in a plastic tube, and the coloring solution is in the cap of the tube. Appearance of the coloring solution: a clear brown liquid; The volume of the coloring solution is 2 ml ± 5%; the pH of the coloring solution is in the range of 4 to 7 units. Mechanism of action: after applying the staining solution to the epithelial tissue, in the presence of atypical cells, folic acid, via the folate receptors on the surface of these cells, quickly enters the cytoplasm, is oxidized by the active oxygen present in the cell, and the tampon stains at different intensities. Normal cells have a low content of active oxygen, so there is little expression of folic acid receptors on the surface of the cells and the tampon does not stain after the reaction.
Results
The study included 20 (100%) patients, of which: with CIN I - 5 (25%), CIN II - 3 (15%), CIN III - 4 (20%), patients with cervical cancer - 5 (25 %), with cervical erosion - 2 (10%) and 1 (5%) women with a visually unchanged cervix. The age of women ranged from 29 to 64 years, the average age was 40 ± 0.7 years (p>0,5). In case CIN1, the tampon was colored dark green, with CIN2 it was blue-green, with CIN3 it was blue, and with cervical cancer, it was dark gray and black. The results obtained fully met the requirements of the regulatory document, the sensitivity of the coloring solution was 98%, the specificity was 95%.
Conclusions
Thus, the modified CIN-DIAG coloring solution has the advantages of economy, affordability, low technical requirements, safety and non-invasiveness, as a result of which it can be successfully applied in remote regions of the country.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
34P - Clinical significance of neoadjuvant dose-dense chemotherapy for II and III stage breast cancer: A meta-analysis of published studies
Presenter: Meng chen Liu
Session: e-Poster Display Session
35P - Pathological response to weekly nabpaclitaxel and carboplatin followed by anthracycline regimen in triple negative breast cancer
Presenter: Goteti Sharat Chandra
Session: e-Poster Display Session
36P - Survival in patients with contralateral breast cancer
Presenter: Sergey Kamishov
Session: e-Poster Display Session
37P - Correlation between haematological toxicity with quality of life in breast cancer patients after first-cycle chemotherapy
Presenter: felix Wijovi
Session: e-Poster Display Session
38P - Evaluation of the prognostic value of innate immunity-related biomarkers in early breast cancer (BC)
Presenter: Veronica Martini
Session: e-Poster Display Session
39P - CSF-1R inhibitor (C019199) enhances antitumor effect in combination with anti-PD-1 therapy on murine breast cancer models
Presenter: Jiani Zheng
Session: e-Poster Display Session
40P - Molecular subtypes and imaging phenotypes of breast cancer: MRI
Presenter: Yulduz Khatamovna
Session: e-Poster Display Session
41P - Mir-223 overexpression is associated with increased expression of EGFR and worse prognosis in Indonesian TNBC patients
Presenter: Ibnu Purwanto
Session: e-Poster Display Session
42P - Impact of germline mutations on breast cancer prognosis in Kazakh population
Presenter: Dilyara Kaidarova
Session: e-Poster Display Session
50P - Efficacy and safety analysis of pyrotinib in lapatinib resistant HER2-positive metastatic breast cancer: A retrospective study
Presenter: Yijia Hua
Session: e-Poster Display Session